Arch Biopartners and the Fraser Health Authority enter into a Clinical Trial Agreement for the Phase II Cardiac Surgery-Associated AKI Trial

Core Insights - Arch Biopartners Inc. has entered into a Clinical Trial Agreement with Fraser Health Authority to initiate patient recruitment for its Phase II trial of LSALT peptide aimed at preventing and treating cardiac surgery-associated acute kidney injury [1][2] Company Overview - Arch Biopartners Inc. is a therapeutic biotech company focused on developing novel drugs for acute kidney injury (AKI) and chronic kidney disease (CKD), targeting inflammation- and toxin-related kidney injuries [4] - The company's development pipeline includes distinct, mechanism-based approaches to address serious unmet needs in kidney care, affecting over 800 million people globally [4] Clinical Trial Progress - Royal Columbian Hospital (RCH) is now the ninth site activated globally for the trial and the fourth site in Canada to recruit patients [2] - Other Canadian sites, including Toronto General Hospital, St. Michael's Hospital, and the University of Calgary, are actively enrolling patients [3] - The company is in discussions with additional leading cardiac surgery centers in Canada and the United States to expand the trial [3]